Home > Boards > US Listed > Medical - Drugs > Antares Pharma, Inc. (ATRS)

Yes good news, but the major revenues will

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
hyperopia Member Profile
 
Followed By 11
Posts 370
Boards Moderated 0
Alias Born 09/10/17
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/21/2020 6:29:30 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/21/2020 6:28:04 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/21/2020 6:24:52 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2020 1:19:20 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/11/2020 7:08:02 AM
Antares Pharma Announces Full-Year 2020 Net Revenue Guidance Range of $135 to $155 Million GlobeNewswire Inc. - 1/27/2020 7:00:10 AM
Antares Pharma Appoints Edward Tykot Senior Vice President, Corporate Development GlobeNewswire Inc. - 12/10/2019 7:00:10 AM
Antares Pharma Social Media Campaign for XYOSTED® Wins MarCom Platinum Award GlobeNewswire Inc. - 12/6/2019 7:00:10 AM
Antares Pharma to Present at the 31st Annual Piper Jaffray Healthcare Conference GlobeNewswire Inc. - 11/27/2019 5:51:22 PM
Antares Pharma Enters Into a Global Development Agreement With Idorsia Pharmaceuticals Ltd. GlobeNewswire Inc. - 11/19/2019 7:00:00 AM
Antares Pharma Enters Into a Global Development Agreement With Idorsia Pharmaceuticals Ltd. GlobeNewswire Inc. - 11/19/2019 1:00:00 AM
Antares Pharma to Present at the Jefferies 2019 London Healthcare Conference GlobeNewswire Inc. - 11/13/2019 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/5/2019 4:16:28 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/5/2019 7:31:28 AM
Antares Pharma Reports Third Quarter 2019 Operating and Financial Results GlobeNewswire Inc. - 11/5/2019 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/4/2019 7:02:13 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/4/2019 7:00:22 AM
Antares Pharma Announces Receipt of Final Payment From Sale of Zomajet™ Needle-Free Delivery System GlobeNewswire Inc. - 10/31/2019 7:00:05 AM
Antares Pharma to Report Third Quarter 2019 Financial and Operating Results GlobeNewswire Inc. - 10/29/2019 7:00:05 AM
Gazit Globe Offer to Acquire All Minority Shareholder Interests in Subsidiary Atrium Has Not Been Approved GlobeNewswire Inc. - 10/25/2019 10:41:10 AM
Antares Pharma Announces Two Poster Presentations at the 2019 Sexual Medicine Society Scientific Annual Meeting GlobeNewswire Inc. - 10/24/2019 7:00:05 AM
Gazit Globe Reaffirms its Commitment and Price GlobeNewswire Inc. - 10/11/2019 2:41:57 PM
Antares Pharma to Present at the Ladenburg Thalmann 2019 Healthcare Conference GlobeNewswire Inc. - 9/17/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/10/2019 5:01:34 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/6/2019 4:02:45 PM
hyperopia   Friday, 11/22/19 09:15:04 AM
Re: H2R post# 4694
Post # of 4751 
Yes good news, but the major revenues will be a few years away. At the Jefferies Conference in London, Antares provided a little color on the new partnership, and they believe there is huge potential for this product. There are well established P2Y12 blockbuster products like Plavix and Brillinta already on the market for cronic use but Idorsia’s Selatogrel will be used in an emergency, acute setting at the onset of heart attack symptoms. Although terms haven’t been disclosed, Antares will supply a fully assembled product at cost plus margin, and said the royalty will be similar to their arrangements with their other partnerships which are a single to double-digit royalty on end sales. From a royalty standpoint, it could be very meaningful since the product will address a large, global population. They plan to start a phase 2 crossover (bridging) trial, and if successful, will prepare to supply a very large, global, Phase III study in early 2021. If the product is eventually approved, from a marketing standpoint, it will be the largest product for Antares to date.


This article, makes it sound like the bridging studies may have actually started back in September.

Phase 2 data of selatogrel, Idorsia’s highly-selective P2Y12 receptor antagonist, presented at ESC 2019
September 03, 2019
https://www.globenewswire.com/news-release/2019/09/03/1910237/0/en/Phase-2-data-of-selatogrel-Idorsia-s-highly-selective-P2Y12-receptor-antagonist-presented-at-ESC-2019.html

Guy Braunstein, MD and Head of Idorsia Global Clinical Development, added:
“The Phase 2 data demonstrate that subcutaneous administration of selatogrel 16mg in patients with stable CAD and patients with AMI has a rapid onset of action, within 15 minutes, with the effect extending over 4-8 hours. Based on the speed at which selatogrel takes effect, the duration of that effect, and the safety and tolerability profile, self-administration of selatogrel at the very onset of symptoms of a suspected AMI has potential as a highly innovative approach to AMI management.”
In consultation with health authorities, Idorsia is preparing a large, international, multi-center, Phase 3 study to investigate the efficacy and safety of subcutaneous self-administration of selatogrel for the treatment of a suspected AMI in patients with an history of AMI. Participating patients will be trained on when to inject and instructed on how to self-administer treatment. An integrated drug delivery device is being developed through usability and reliability studies to ensure functional efficacy can be demonstrated ahead of the Phase 3 study.


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist